BIOMARKERS
    71.
    发明申请
    BIOMARKERS 审中-公开
    生物标志

    公开(公告)号:US20150141273A1

    公开(公告)日:2015-05-21

    申请号:US14396522

    申请日:2013-04-26

    Abstract: The invention provides a method for screening for colorectal cancer, the method comprising: screening a biological sample from an individual for one or more biomarkers selected from the group defined in Table 1 and/or Table 6, wherein the presence of or increased expression of the one or more biomarkers relative to a control sample is indicative that the individual is at risk of suffering from or is suffering from colorectal cancer. The invention also provides an array and kit suitable for use in the methods of the invention, methods of treating colorectal cancer and therapeutic agents for use in methods of treating cancer.

    Abstract translation: 本发明提供了筛选结肠直肠癌的方法,该方法包括:从个体中筛选一种或多种选自表1和/或表6中定义的组的生物标志物的生物样品,其中存在或增加表达 一个或多个相对于对照样品的生物标志物表明个体处于患有或正在患有结肠直肠癌的风险中。 本发明还提供适用于本发明方法的阵列和试剂盒,治疗结肠直肠癌的方法和用于治疗癌症的方法中的治疗剂。

    INHIBITION OF MYCOBACTERIAL TYPE VII SECRETION

    公开(公告)号:US20220280487A1

    公开(公告)日:2022-09-08

    申请号:US17638086

    申请日:2020-08-26

    Abstract: The invention relates to compounds and pharmaceutically acceptable salts thereof, and to their medical use. Exemplary medical uses are the prevention and treatment of a bacterial infection, for example, a mycobacterial infection, such as a Mycobacterium tuberculosis infection, e.g., in a respiratory system and/or extrapulmonic. The invention further relates to a use of such compounds, pharmaceutically acceptable salts thereof or prodrugs of the compounds as chemotherapeutic agents. Also, the invention relates to a use of such compounds, pharmaceutically acceptable salts thereof or prodrugs of the compounds for inhibiting mycobacterial type VII secretion.
    The compounds have the following formula wherein Q and X are, respectively, CH and C, CR2 and C, CH and N, CR2 and N, or N and C; R1 is hydrogen, halide or optionally substituted linear or branched alkoxy having 1 or 2 carbon atoms; R2 is independently selected from hydrogen, halide or optionally substituted linear or branched alkoxy having 1 or 2 carbon atoms, and R3 is optionally substituted linear or branched alkoxy having 1-6 carbon atoms, haloalkyl having 1-6 carbon atoms, n-propyl, 2-propenyl, 2-propynyl, or n-pentyl, or a pharmaceutically acceptable salt of the compound, for use in the prevention or treatment of a bacterial infection.

Patent Agency Ranking